biopharma industry
按立场 · 1 视角 本期全站
Endpoints News · United States · US biotech Oblenio Bio raises US$62m Series B for an autoimmune T-cell engager optioned from China's Leads Biolabs
Industry read on the raise, the Leads Biolabs origin and the crowded autoimmune T-cell-engager field, part of a wave of Chinese-discovered assets advanced by US NewCos with Western venture money.
“Autoimmune disease company Oblenio Bio clinches $62M in Series B.”